StockData

8x8 vs Hinge Health

EGHT and HNGE side by side, both in computer programming, data processing, and other computer related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EGHT and HNGE compare

Hinge Health is the larger company, worth 31 times as much as 8x8 ($9.2B against $302M).

Hinge Health grew revenue faster over the last twelve months (49.8% versus 3.7% for 8x8).

Hinge Health keeps more of each dollar of sales as profit, with a net margin of 15.1% compared with 0.64% at 8x8.

Hinge Health scores higher on the StockData Score (11 against 6 for 8x8), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEGHTHNGE
Size and price
Market cap$302M$9.2B
Share price$2.09$114.32
Change, 1 year12.4%130%
Change, 5 years−90.8%–
Beta (5Y)2.001.68
Employees1,8191,437
StockData Score
Total score611 (better)
Valuation score1 (better)0
Growth score13 (better)
Performance score3 (better)2
Health score16 (better)
Dividend score00
Valuation
P/E52.3×–
P/S0.4× (better)12.8×
P/B2.0× (better)26.8×
EV/EBITDA22.8× (better)89.8×
P/FCF5.3× (better)31.8×
FCF yield18.9% (better)3.1%
Fair value$1.65–
Margin of safety−26.5%–
Growth
Revenue growth (TTM)3.7%49.8% (better)
Revenue growth, 5Y average6.7%–
Profitability
Gross margin63.3%84.5% (better)
Operating margin3.1%13.0% (better)
Net margin0.64%15.1% (better)
FCF margin7.6%40.3% (better)
Return on equity3.5%42.1% (better)
Return on invested capital4.6%–
Financial health
Debt / equity2.08 (better)0.00
Net debt / EBITDA9.53–
Interest coverage1.3×–
Current ratio1.051.34 (better)
Altman Z-score−0.2611.29 (better)
Piotroski F-score6 (better)5
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions71.4%72.0%
Held by insiders10.1%50.7%
Insider net buying, 12 months−$562K (better)−$517M
Short interest, % of float2.2%15.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.